The role of erbB-2 and its ligands in growth control of malignant breast epithelium

Ruth Lupu, Robert B. Dickson, Marc E. Lippman

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


The erbB-2 (HER-2, neu) protooncogene is overexpressed on the surface of about 25% of human breast cancers. It is homologous to epidermal growth factor receptor and a putative growth factor receptor. Overexpression in breast, ovarian and gastric cancers is associated with a worse prognosis. We have recently discovered two ligands for this receptor. They both induce receptor phosphorylation. At low concentrations both induce clonogenic growth of overexpressing cells; at higher concentrations both are growth inhibitory. Both can overcome the inhibitory effects of both monoclonal antibodies directed against the ligand binding site and soluble extracellular domain. These ligands may form an attractive basis for antitumor therapy.

Original languageEnglish (US)
Pages (from-to)229-236
Number of pages8
JournalJournal of Steroid Biochemistry and Molecular Biology
Issue number1-3
StatePublished - Sep 1992

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Endocrinology
  • Clinical Biochemistry
  • Cell Biology


Dive into the research topics of 'The role of erbB-2 and its ligands in growth control of malignant breast epithelium'. Together they form a unique fingerprint.

Cite this